Market Overview

A Peek Into The Market Before The Trading Starts

Related WDC
Western Digital: 16-18% Upside Based On Analyst Commentary
Western Digital Q4 Conference Call
Tech Sector Lags as EMC, Juniper Sink (Fox Business)
Related BIIB
After Recent Surge, Are Biotech ETFs Back on Track? - ETF News And Commentary
UPDATE: Morgan Stanley Reiterates On Biogen Idec Following Plegridy Approval
Don't Panic Over Recent Tech Turmoil (Fox Business)

Pre-open movers US stock futures are higher this morning. Futures for the Dow Jones Industrial Average surged 30 points to 13,295.00 and S&P 500 index futures rose 4.60 points to 1,433.00. Nasdaq 100 futures gained 4.75 points to 2,718.00.

A Peek Into Global Markets European markets were lower today. The STOXX Europe 600 Index fell 0.16%, London's FTSE 100 Index dropped 0.16%, French CAC 40 Index declined 0.11% and German DAX 30 index fell 0.17%.

Asian markets ended mixed, with Japan's Nikkei Stock Average dropping 0.15%, China's Shanghai Composite gaining 0.10% and Australia's S&P/ASX 200 rising 0.11%. Hong Kong's Hang Seng index rose 0.65% and India's Sensex dropped 0.69%.

Broker Recommendation Analysts at Citigroup downgraded Western Digital (NASDAQ: WDC) from “buy” to “sell.” The target price for Western Digital has been lowered from $53 to $32.

Western Digital shares dropped 1.07% to $36.20 in pre-market trading.

Breaking news

  • Biogen Idec (NASDAQ: BIIB) announced new data from studies evaluating oral BG-12 (dimethyl fumarate), which provide further evidence supporting its strong clinical and radiological effects in people with relapsing-remitting multiple sclerosis (RRMS) and reinforce its favorable safety profile seen to date. To read the full news, click here.
  • LINN Energy LLC (NASDAQ: LINE) announced today the pricing of the initial public offering of 30,250,000 common shares of LinnCo LLC (NASDAQ: LNCO), a wholly-owned subsidiary of LINN, at $36.50 per common share. To read the full news, click here.
  • Lexicon Pharmaceuticals (NASDAQ: LXRX) announced positive, top-line data from a recently completed Phase 2 study in carcinoid syndrome with telotristat etiprate. To read the full news, click here.
  • AU Optronics (NYSE: AUO) signed patent cross-license agreements with E-Ink Holdings and Hydis Technologies Co Ltd, E-Ink's South Korean subsidiary, respectively. To read the full news, click here.

Posted-In: Citigroup US Stock FuturesNews Futures Global Pre-Market Outlook Markets

 

Related Articles (BIIB + AUO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters